New Delhi: A recent study by the Indian Council of Medical Research revealed that Bharat Biotech’s Covid-19 vaccine, Covaxin, is effective against the prevalent Delta Plus variant of Covid-19.
Bharat Biotech collaborated with the Indian Council of Medical Research (ICMR) National Institute of Virology to develop Covaxin (NIV).
Because of its impact on existing vaccines, the Delta Plus variant of coronavirus is a global public health concern.
Bharat Biotech reported last month that Covaxin had a 77.8 percent efficacy against symptomatic Covid-19 and a 65.2 percent protection against the new Delta variant. The vaccine maker has completed the final analysis of Covaxin efficacy from Phase 3 trials.
The Covaxin vaccine is the first Covid-19 vaccine that has been completely developed in India.
In terms of safety and immunogenicity, pre-clinical studies in small animals and hamsters yielded promising results. Further research in rhesus macaques confirmed Covaxin’s remarkable safety and protective efficacy. The candidate vaccine’s safety profile was demonstrated in phase 1 and phase 2 clinical trials involving 755 participants, with seroconversion rates of 98.3 percent and 81.1 percent on days 56 and 104, respectively.
Bharat Biotech submitted all documents required for Emergency Use Listing (EUL) for Covaxin to WHO on Tuesday, as of July 9, and the agency’s review process had begun, informed Minister of State for Health Bharati Pravin Pawar in Rajya Sabha.
In response to a question about whether the government is aware that the COVID-19 vaccine Covaxin, which is used in India, is not recognised by many countries, Pawar stated that the government is aware that Covaxin is not currently on the WHO Emergency Use Listing (EUL).
The WHO review process has begun. In a written response, she stated that WHO typically takes up to six weeks to make a decision on Emergency Use Listing (EUL) submissions.
Covaxin has already been approved for emergency use in 16 countries, including Brazil, Mexico, the Philippines, and Iran. Covaxin is one of three vaccines currently being used in India for the country’s nationwide immunisation drive. The other two vaccines are Covishield from the Serum Institute of India and Sputnik from Russia.